Business Context and Reporting Period
Company: Aytu BioScience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2018 (Event Date)
Reporting Period: Single event disclosure regarding a material definitive agreement.
Key Financial Metrics
This filing does not provide standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity). The financial impact is limited to the terms of a new license agreement:
- Cash Payment: The Company made an immediate cash payment to Magna Pharmaceuticals, Inc. as consideration for the license. The specific amount is not disclosed in this text.
- Future Obligations: The Company is obligated to pay royalty fees to Magna until 2025.
Material Changes
The primary material change is the entry into an exclusive, sub-licensable, royalty-bearing license agreement with Magna Pharmaceuticals, Inc. for the product Zolpimist in the United States and Canada. This agreement was executed on June 11, 2018.
Guidance, Outlook, and Risks
- Agreement Terms: The license may be terminated by either party upon a material breach. The Company may terminate at its discretion with 60 days' prior written notice and payment of a termination fee (amount not specified).
- Confidentiality: The Company intends to seek confidential treatment for certain terms and provisions of the License Agreement.
- Disclosure: A press release announcing the agreement was issued on June 13, 2018, but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific amount of the upfront cash payment made to Magna Pharmaceuticals, Inc.
- Review the full text of the License Agreement (to be filed as an exhibit to the Form 10-K for the fiscal year ending June 30, 2018) to determine the royalty rate and termination fee amount.
- Confirm the commercial status and regulatory standing of Zolpimist in the U.S. and Canada.
- Assess the impact of the royalty obligations on future cash flow projections through 2025.